June 20, 2019 / 5:42 PM / 3 months ago

BRIEF-Valneva Announces Mutual Agreement With GSK To End Strategic Alliance Agreement

June 20 (Reuters) - Valneva SE:

* VALNEVA ANNOUNCES MUTUAL AGREEMENT WITH GSK TO END STRATEGIC ALLIANCE AGREEMENT; REGAINS CONTROL OF RESEARCH AND DEVELOPMENT

* VALNEVA - GSK AND CO HAVE DECIDED, BY MUTUAL AGREEMENT, TO END STRATEGIC ALLIANCE AGREEMENT, ORIGINALLY AGREED BETWEEN NOVARTIS AND INTERCELL

* VALNEVA SE - LYME VACCINE DEVELOPMENT PROGRAM IS FULLY FUNDED THROUGH PHASE 2

* VALNEVA - CO TO PAY EUR 9 MILLION TO GSK IMMEDIATELY & UP TO A FURTHER EUR 7 MILLION IN MILESTONES RELATING TO MARKETING APPROVALS OF ITS LYME VACCINE

* VALNEVA SE - AS PART OF GSK’S ONGOING INITIATIVE TO ALLOCATE CAPITAL TO FEWER, HIGHEST PRIORITY AREAS, ELECTED TO COME TO AN EARLY TERMINATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below